1. Home
  2. TNYA vs NERV Comparison

TNYA vs NERV Comparison

Compare TNYA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

HOLD

Current Price

$0.68

Market Cap

153.2M

Sector

Health Care

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$3.52

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNYA
NERV
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
166.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
TNYA
NERV
Price
$0.68
$3.52
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$5.33
$10.50
AVG Volume (30 Days)
1.6M
127.7K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
54.96
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$2.01
52 Week High
$2.35
$12.46

Technical Indicators

Market Signals
Indicator
TNYA
NERV
Relative Strength Index (RSI) 50.35 30.08
Support Level $0.65 N/A
Resistance Level $0.82 $4.73
Average True Range (ATR) 0.03 0.29
MACD 0.00 -0.13
Stochastic Oscillator 77.32 1.37

Price Performance

Historical Comparison
TNYA
NERV

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: